Navigation Links
PharmaRoth Labs, Inc. Announces Trading Symbol Change
Date:5/1/2013

LAS VEGAS, May 1, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTCPink:  FROI) (the "Company") announced today its name change to PharmaRoth Labs, Inc. will be effective upon the open of trading on May 2, 2013.  The Company's common stock will begin trading under the new trading symbol "ROTH".

"We are pleased to announce the effectiveness of our name and trading symbol changes as they now more adequately reflects our focus on the production, marketing, and distribution of Sucanon®," stated the Company's CEO Luis Lopez , "It also completes the entry into the public marketplace and of our reorganized company so our shareholders will be more able to identify us."

About Sucanon® 
Sucanon® is a dietary supplement containing natural ingredients. In certain ex-US countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers". Pre-clinical and clinical studies conducted ex-US have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico. Sucanon® will be marketed as a dietary supplement in the US.

For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.feroindustries.com.

About PharmaRoth Labs, Inc.

PharmaRoth Labs, Inc. (OTCPink: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor relations contact:

Michael Irving - Paramount Advisors, LLC (407) 878-5462


'/>"/>
SOURCE PharmaRoth Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaRoth Labs, Inc. Files New Dietary Ingredient Notification with the US Food and Drug Administration (FDA)
2. Fero Industries, Inc. Changes Name to PharmaRoth Labs, Inc.
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. Paratek Pharmaceuticals Announces Expanded FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline
5. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
6. GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
7. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
8. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
9. Cardica Announces Fiscal 2013 Third Quarter Financial Results
10. Sensus Healthcare Announces its Exhibitor Attendance at the 45th ACMS Annual Meeting
11. Dr. David Altamira Announces New Non-Surgical Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
Breaking Medicine News(10 mins):